Sarasota Cardiologist Dr. Shahawy, MD, MS, FACP, FESC, FSCCT, FASH, FAHA, FACC Receives
International Recognition in Vienna, Austria
Dr. El Shahawy (center) holding the Golden Doctor Diploma presented to him at The University of Vienna, Austria by the President of the University [at right] on June 4, 2014. Professor Jay Cohn (at Shahawy's left) the Director of the Cardiovascular Disease Prevention Center at the University of Minnesota and Professor Konrad Steinbach (far left), President of the Austrian Heart Foundation
SARASOTA, Fla. – Dr. Mahfouz El Shahawy, Medical Director of the Cardiovascular Health Assessment Center in Sarasota and Clinical Professor of Medicine at the Universities of Florida and South Florida, was honored by the University of Vienna, Austria on June 4, 2014 with the Golden Doctor Diploma for his achievements in the area of early cardiovascular disease prevention, including more than 100 discoveries, publications, and lectures.
Dr. Shahawy graduated Summa Cum Laude from the University of Vienna, Austria in 1962 and received the Ring of Honor directly from the President of Austria during a special graduation ceremony. “Dr. El Shahawy was the first non-Austrian in the history of the University of Vienna til today to achieve this honor,” said Professor Steinbach, President of the Austrian Heart Foundation.
On June 4, 2014 a special celebration ceremony was held in Dr. Shahawy’s honor at the University of Vienna to present him with the “The Golden Doctor Diploma of the University of Vienna.” Many distinguished guests from around the world were in attendance, including the Egyptian Ambassador to Austria, Sarasota Memorial Healthcare Foundation President Alex Quarles and cardiology department professors/ chiefs from the United States and Austria.
“I am very pleased to receive this honor and share it with you. I would like to thank everyone who has contributed and supported our efforts in the area of early cardiovascular health assessment and disease prevention at the Cardiovascular Center of Sarasota,” said Dr. Shahawy.
Dr. Shahawy’s work has resulted in over 100 publications and recognition by many national and international organizations including the University of Vienna [ Dr El Shahawy’s Alma Mater], and most recently by the President of the World Heart Federation following Dr. Shahawy’s presentations at the World Congress of Cardiology meeting in Melbourne, Australia.
Dr. Shahawy Guest Speaker at 42nd Annual Meeting of the Egyptian Society of Cardiology
Dr. Shahawy was invited to be a guest speaker at the 42nd Annual Meeting of Egyptian Society of Cardiology held in Cairo, Egypt February 2015.
Dr. Shahawy giving one of his presentations at the 42nd Annual Meeting of Egyptian Society of Cardiology.
Doctor Shahawy in Scene Magazine 2015
Article from Scene Magazine Interview with Dr. Shahawy:
“One ounce of early cardiovascular prevention is better than pounds of late cure.”
Sarasota is home to many people who have achieved world renown in their professions from music and sports to business, and also in medicine. Dr. Mahfouz El Shahawy, Medical Director of the Cardiovascular Health Assessment Center at the Cardiovascular Center of Sarasota and Clinical Professor of Medicine at the Universities of Florida and South Florida, has practiced in Sarasota while earning an international reputation for advancing the field of cardiovascular medicine. This year, he celebrates his 40th anniversary here. Throughout his career, he has earned many awards, and most recently, received the Golden Doctor Diploma from his alma mater, the University of Vienna, Austria, for his achievements in early cardiovascular disease prevention. Those achievements include more than 100 discoveries, publications, and lectures. He also is only one of eight recipients, and the first non-Austrian in the university’s history, to receive the Ring of Honor from Austria’s President upon his graduation.
Dr. Shahawy maintains a busy cardiology practice, and also works tirelessly on his passion to promote early detection and prevention of cardiovascular disease. “Why is early detection so important?” he asks. “For those suffering heart attacks, 50 percent don’t make it to the hospital.” To aid in early detection, he has adopted an 18 point Heart Inspection, which goes beyond the usual assessments to determine cardiovascular disease risk. He also hosts an annual cardiology symposium in Sarasota, which is being held on Feb. 7 at Sarasota Memorial Hospital Auditorium.
With a career-long interest in research, nurtured during his fellowship at the renowned Mayo Clinic, Dr. Shahawy has participated in more than 95 clinical cardiovascular trials involving multinational centers. Currently, he is conducting research and clinical trials on drugs to aid those with metabolic syndrome, diabetic heart disease, heart failure, hypertension, atrial fibrillation, and stroke prevention. “In this era of evidence-based medicine, our treatments should be based on facts, results, and personalized patient-based care by qualified specialists and state of the art tools, ” Dr. Shahawy says, “but it still comes down to people taking that first step to get assessed.”
Sarasota Cardiologist Dr. El Shahawy, M.D., MS,
FACP, FESC, FSCCT, FASH, FAHA, FACC
Received international recognition as a Principal Investigator and Co-Author in a landmark clinical trial utilizing a new investigational agent (Alirocumab) for treating high bad cholesterol at the Annual Meeting of the
European Society of Cardiology August 31, 2014 in Barcelona, Spain
Caption: Dr. El Shahawy at the Annual Meeting of the European Society of Cardiology 2014 in Barcelona, Spain.
SARASOTA, Fla. – Dr. Mahfouz El Shahawy, Medical Director of the Cardiovascular Health Assessment Center in Sarasota and Clinical Professor of Medicine at the Universities of Florida and South Florida, was privileged to be a principal investigator and co-author in a landmark paper presented at the Late Breaking Clinical Trial Session on Coronary Artery Disease and Lipids at the European Society of Cardiology’s Annual Meeting 2014.
The paper presented showed for the first time the efficacy and safety of this new investigational drug, PCSK9 (Alirocumab) in reducing the high bad cholesterol (LDL-C) by over 61% on top of the maximum tolerated dose of statin taken by 2,341 high cardiovascular risk subjects, thus bringing them to their target goal for their LDL-C (less than 70 mg/dL). This news was very well received and welcomed by the over 29,000 attendees at the European Society of Cardiology meeting.
The title of the paper presented where Dr. El Shahawy was a Principal Investigator and Co-Author was:
Long-term safety, tolerability and efficacy of alirocumab versus placebo in high cardiovascular risk patient: first results from the ODYSSEY LONG TERM study in 2,341 patients.
“I am very pleased and honored to have been a principal investigator and co-author in this landmark presentation on the reduction of bad cholesterol by over 61% above any current medication used for bad cholesterol reduction in high risk cardiovascular patients that are not at their goal. Bad cholesterol [LDL C] is a major cardiovascular risk factor. Hopefully with this new finding we would be able to reduce the risk of cardiovascular morbidity and mortality from atherosclerotic cardiovascular disease.
We thank all our patients who volunteered for this landmark clinical trial. Every Sarasota County Resident should be proud that Sarasota, Florida has been represented on this landmark trial and presentation at the international level. With this finding dealing with the reduction of high bad cholesterol in high risk cardiovascular patients not well controlled with a current statin, every Sarasota County Resident should be very proud that SARASOTA has been contributing to this landmark clinical trial for advancing the treatment of this major risk factor for coronary artery disease. ” said Dr. Shahawy.
Our Cardiovascular Health Assessment Center of Sarasota, Florida had another presentation at the European Society of Cardiology Annual Meeting dealing with the abnormal rise of Blood Pressure post protocol exercise in normotensive subjects, which was associated with early cardiovascular structural and functional abnormalities. Thus helping early cardiovascular risk stratification in subjects with normal blood pressure at rest.
We would also like to thank all the participants in the program for early cardiovascular health assessment at the Cardiovascular Health Assessment Center located at the Cardiovascular Center of Sarasota.
For more information about our publications and discoveries in the area of early cardiovascular disease prevention or participation in clinical trials, visit www.cardiologycenter.net .
If you have any questions, please call Ramona Stevens at 941-366-9800.
Medical News for Immediate Release: July 2, 2014
The FMA congratulates member Mahfouz El Shahawy,M.D., who received the Golden Doctor Diploma last month from the University of Vienna, Austria. Dr. El Shahawy was recognized for his achievements in early cardiovascular disease prevention, including more than 100 discoveries, publications and lectures. He is Medical Director of the Cardiovascular Health Assessment Center in Sarasota and Clinical Professor of Medicine at the University of Florida and the University of South Florida.
If you have any questions, please call Ramona Stevens at (941) 366-9800 .